Insider filing
Traded Sep 1 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Sep 2, 2026 · Filed Sep 3, 2026
Autolus Therapeutics's U.S. CCO & Country Gen Manager sold $16K of Autolus Therapeutics shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$15,682
Shares × reported transaction price
22 days after results of Aug 11, 2026, 69 days before results of Nov 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −16.1% | −0.8% | −15.3% |
| 30 days | −18.3% | +0.6% | −18.9% |
Past results only. Not a forecast.
Insider filing
Traded Sep 1 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Insider filing
Traded Sep 1 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Insider filing
Traded Jun 29 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.